Scoping Review Finds Preclinical Promise but Limited Clinical Evidence for Cannabis in Rheumatoid Arthritis
Preclinical studies show promising anti-inflammatory and analgesic effects of cannabinoids for rheumatoid diseases, but clinical studies are scarce with mixed results and no recommendations exist.
Quick Facts
What This Study Found
Preclinical studies demonstrated cannabinoids can halt disease progression and relieve pain. Clinical studies are scarce with mixed results. No clinical recommendations exist.
Key Numbers
Preclinical: promising. Clinical: scarce with mixed results. No recommendations. Conditions: RA, OA, fibromyalgia.
How They Did This
Scoping review examining preclinical and clinical data on cannabis for RA, osteoarthritis, and fibromyalgia.
Why This Research Matters
Many patients already use cannabis without clinical guidance. The evidence base is insufficient for practice.
The Bigger Picture
The disconnect between preclinical promise and clinical reality is a recurring theme across cannabis medicine.
What This Study Doesn't Tell Us
Heterogeneous studies. Limited clinical data. Variable formulations and dosing.
Questions This Raises
- ?What evidence threshold is needed before clinical recommendations?
- ?Which cannabinoid formulation shows most promise?
Trust & Context
- Key Stat:
- Promising preclinical data but no clinical recommendations for cannabis in RA
- Evidence Grade:
- Scoping review limited by scarce and heterogeneous clinical evidence.
- Study Age:
- Published 2023.
- Original Title:
- Cannabis and Rheumatoid Arthritis: A Scoping Review Evaluating the Benefits, Risks, and Future Research Directions.
- Published In:
- Rambam Maimonides medical journal, 14(4) (2023)
- Authors:
- Paland, Nicole, Hamza, Haya(2), Pechkovsky, Antonina(2), Aswad, Miran, Shagidov, Dayana, Louria-Hayon, Igal
- Database ID:
- RTHC-04832
Evidence Hierarchy
Maps out the available research on a broad question.
What do these levels mean? →Frequently Asked Questions
Can cannabis help with rheumatoid arthritis?
Lab studies suggest anti-inflammatory and pain-relieving properties, but clinical evidence is scarce with mixed results.
Should RA patients try cannabis?
No established clinical recommendations exist. The evidence is insufficient.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-04832APA
Paland, Nicole; Hamza, Haya; Pechkovsky, Antonina; Aswad, Miran; Shagidov, Dayana; Louria-Hayon, Igal. (2023). Cannabis and Rheumatoid Arthritis: A Scoping Review Evaluating the Benefits, Risks, and Future Research Directions.. Rambam Maimonides medical journal, 14(4). https://doi.org/10.5041/RMMJ.10509
MLA
Paland, Nicole, et al. "Cannabis and Rheumatoid Arthritis: A Scoping Review Evaluating the Benefits, Risks, and Future Research Directions.." Rambam Maimonides medical journal, 2023. https://doi.org/10.5041/RMMJ.10509
RethinkTHC
RethinkTHC Research Database. "Cannabis and Rheumatoid Arthritis: A Scoping Review Evaluati..." RTHC-04832. Retrieved from https://rethinkthc.com/research/paland-2023-cannabis-and-rheumatoid-arthritis
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.